Target-D:钻石临床预测工具用于基层医疗抑郁症状分诊与靶向治疗的分层个体随机对照试验研究方案
Target-D为个体随机对照试验,拟纳入1320例基层医疗抑郁症状患者,按诊所和抑郁症状严重度分层随机分为干预组(依据CPT预测严重度匹配治疗推荐)与对照组(常规护理加注意力控制),主要结局为3个月抑郁症状严重度。研究旨在检验CPT能否较常规护理降低3个月抑郁症状。
要点
- CPT预测3个月后抑郁症状严重度并分为轻微/轻度、中度、重度三组,给出匹配治疗推荐。
- 主要结局为3个月抑郁症状严重度,随访至12个月。
- 研究为个体随机对照试验,按诊所和抑郁症状严重度分层随机。
核心结论
- 研究旨在检验使用CPT较常规护理能否降低3个月抑郁症状严重度。
- 作者认为若证实有效,该工具可协助全科医生实施阶梯式心理健康照护模式。
研究设计与样本
- Target-D为个体随机对照试验,拟纳入1320例基层医疗抑郁症状患者。
- 参与者在诊所候诊室由研究助理邀请,用iPad完成资格筛查,合格者签署知情同意并在专用网站完成CPT。
- 计算机生成分配序列,按诊所和抑郁症状严重度组分层,随机分为干预组(依据预测抑郁症状严重度组匹配治疗推荐)与对照组(常规护理加Target-D注意力控制)。
- 随访在3个月和12个月在线完成,主要结局为3个月抑郁症状严重度。
- 次要结局包括焦虑、心理健康自我效能、生活质量和成本效果,采用意向性分析比较组间总体及按抑郁症状严重度组的结局均值差异。
关键数值与推荐
- CPT预测3个月后抑郁症状严重度,并据此将个体分为轻微/轻度、中度、重度三组,提供匹配治疗推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is a highly prevalent and costly disorder. Effective treatments are available but are not always delivered to the right person at the right time, with both under- and over-treatment a problem. Up to half the patients presenting to general practice report symptoms of depression, but general practitioners have no systematic way of efficiently identifying level of need and allocating treatment accordingly. Therefore, our team developed a new clinical prediction tool (CPT) to assist with this task. The CPT predicts depressive symptom severity in three months' time and based on these scores classifies individuals into three groups (minimal/mild, moderate, severe), then provides a matched treatment recommendation. This study aims to test whether using the CPT reduces depressive symptoms at three months compared with usual care. METHODS: The Target-D study is an individually randomized controlled trial. Participants will be 1320 general practice patients with depressive symptoms who will be approached in the practice waiting room by a research assistant and invited to complete eligibility screening on an iPad. Eligible patients will provide informed consent and complete the CPT on a purpose-built website. A computer-generated allocation sequence stratified by practice and depressive symptom severity group, will randomly assign participants to intervention (treatment recommendation matched to predicted depressive symptom severity group) or comparison (usual care plus Target-D attention control) arms. Follow-up assessments will be completed online at three and 12 months. The primary outcome is depressive symptom severity at three months. Secondary outcomes include anxiety, mental health self-efficacy, quality of life, and cost-effectiveness. Intention-to-treat analyses will test for differences in outcome means between study arms overall and by depressive symptom severity group. DISCUSSION: To our knowledge, this is the first depressive symptom stratification tool designed for primary care which takes a prognosis-based approach to provide a tailored treatment recommendation. If shown to be effective, this tool could be used to assist general practitioners to implement stepped mental-healthcare models and contribute to a more efficient and effective mental health system. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR 12616000537459 ). Retrospectively registered on 27 April 2016. See Additional file 1 for trial registration data.
引用
- Gunn J, Wachtler C, Fletcher S, et al. Target-D: a stratified individually randomized controlled trial of the diamond clinical prediction tool to triage and target treatment for depressive symptoms in general practice: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28728604. doi:10.1186/s13063-017-2089-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。